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Does Pregabalin Have Neuropsychotropic Effects?:  
A Short Perspective 
 
 
 
Pregabalin is a newly developed synthetic gamma-aminobutyric acid (GABA) that is ap-
proved for the treatment of fibromyalgia and several neuropathy. It has been proven to 
show analgesic, anxiolytic, anticonvulsant and sleep enhancement effects, which could be 
applicable in the treatment of a variety of psychiatric disorders. There have been consistent 
reports that unexplained somatic symptoms (i.e., pain) may be a part of psychiatric disor-
ders such as major depressive disorder (MDD) and anxiety disorders. Previous researches 
have also suggested the possible therapeutic potential of anticonvulsants as augmentation 
therapy or monotherapy in the treatment of mood disorders and anxiety disorders. Hence 
this short perspective tries to prompt and facilitate a shifting of researchers’ attention to 
potential neuropsychotropic drug role of pregabalin to treat a wide range of neuropsychiatric 
disorders. 
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Introduction 
 
Pregabalin is a new synthetic molecule and a structural derivative of the inhibitory
neurotransmitter gamma-aminobutyric acid (GABA). Pregabalin does not bind di-
rectly to GABAA, GABAB, or benzodiazepine receptors. In addition it does not augment
GABAA responses in cultured neurons, alter rat brain GABA concentration or have
acute effects on GABA uptake or degradation. However, it was found that prolonged 
application of pregabalin increases the density of GABA transporter protein as well
as the rate of functional GABA transport in cultured neurons. Pregabaline has no in-
volvement with serotonin and dopamine receptors and does not inhibit dopamine, 
serotonin, or noradrenaline reuptake. It has no effects on sodium channels, opiate re-
ceptors, and cyclooxygenase enzyme activity.   
Pregabalin is characterized by its potent high-affinity binding to the α2-δ subunit 
on voltage-gated calcium channels,
1,2 and is approved for management of neuropathic
pain associated with diabetic peripheral neuropathy and postherpetic neuralgia, ad-
junctive therapy for adult patients with partial onset seizures and management of fi-
bromyalgia by the United States Food and Drug Administration (U.S. FDA).
3-6  
The drug may have a strong potential as one of promising neuropsychotropic agents
in the monotherapy or augmentation treatment of various neuropsychiatric disorders
based on its currently available preclinical and clinical data. Hence this short perspec-
tive will review the potential neuropsychotropic effects of pregabalin.   
 
Preclinical Evidence 
 
The recent study of brief treatment with alprazolam initiated immediately after ex-
posure to a traumatizing experience revealed that treatment effectively curbed short- 
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term anxiety-like behaviors, but had no prevention value 
and caused a statistically significant increase in individual 
vulnerability to a trauma-reminder and even more so to 
re-exposure to the index stressor.
7 In addition, benzodia-
zepines have been found not to be associated with the sig-
nificant treatment effects on trauma-related anxiety symp-
toms. However, pregabalin was found to be valuable in the 
alleviation of anxiety symptoms associated with traumatic 
insults without a tendency of vulnerability to subsequent 
stress in a preclinical study.
7 
Pregabalin was also excellent in sleep efficiency as show-
ing an enhancement of slow-wave sleep, reduction of the 
number of midnight awakenings, rapid eye movement 
sleep and sleep-onset latency, which are commonly seen 
in depression, anxiety and pain disorders.
8 In addition, 
pregabalin demonstrated comparable to placebo in cog-
nitive and psychomotor measures, while it was signifi-
cantly superior to alprazolam.
9  
Pregabalin is a GABA analogue without abuse potential, 
although the action mechanism is not same with benzo-
diazepine agents. This property is important in patients 
who need to withdraw benzodiazepine or may have abuse 
propensity. Although the proper principal mechanism of 
pregabalin’s effect on psychiatric disorders may not be 
fully explained, the modulation of calcium channels by 
which reduction of excitatory neurotransmitters release 
should account for its usefulness for various psychiatric 
disorders.
2 It is in line with one of the action mechanisms 
of tricyclic antidepressants (TCAs) that have proven ef-
fectiveness in the treatment of depression, anxiety and 
pain diseases.   
Several line of preclinical data have also suggested the 
neuroprotective effect of pregabalin by anti-apoptotic and 
anti-inflammatory actions, which is useful in protection 
of cognitive function in patients with depression and ge-
riatric psychiatric population.
10 The effects of the long-term 
exposure to pregabalin on neuronal damage and epilepto-
genesis induced by lithium-pilocarpine induced status 
epilepticus in which the effects of pregabalin was assess-
ed in hippocampus and piriform and entorhinal cortices 
in rat brain sections. In the study, pregabalin induced neu-
roprotection in layer II of piriform cortex and layers III-
IV of ventral entorhinal cortex of adult rats.
11 The potential 
neuroprotective effect of pregabalin may add another op-
tional treatment in the area of brain injury, cognitive de-
cline in affective disorders, neurodegenerative disease and 
dementias.  
 
Clinical Evidence 
 
As stated, pregabalin has been U.S. FDA-approved med-
ication for fibromyalgia, which is interesting since fi-
bromyalgia and major depressive disorder (MDD) share 
some commonalities. Numerous studies have found that 
fibromyalgia patients are at increased risk for a lifetime 
history of MDD as compared to normal community sam-
ples.
12 Also, patients with fibromyalgia and MDD share 
symptomatologic similarities. Depressed mood, poor ex-
pression of emotion, decreased energy level, anergia, fa-
tigue, easy upset to psychosocial stressors, aberration of 
sleep architectures and multiple vague somatic symp-
toms.
13 Furthermore, the number of tender points in pa-
tients with fibromyalgia has been found to be correlated 
with depressive symptoms such as depressed mood, fati-
gue, disability, pain, and somatic symptoms as well as 
being connected with functional impairments.
14 
Recently an emerging evidence of potential role of 
pregabalin in the treatment of psychiatric disorders such 
as generalized anxiety disorder (GAD) and social anxiety 
disorder (SAD) has been available. The potential anti-de-
pressive and anti-anxiety effects of pregabalin have been 
established in a number of randomized, placebo-controll-
ed clinical trials (RCTs).
1,15-18 In the first RCT of prega-
balin for GAD,
15 the mean baseline-to-endpoint decreases 
in total Hamilton Anxiety Rating Scale (HARS) score in 
patients with 600 mg/d of pregabalin (-44.4%) were sig-
nificantly greater than the decrease in those given placebo 
(-29.7%), while it was not significantly different com-
paring with lorazepam. This trend was observed as early 
as the week 1 continuing till the end of the study, which 
was replicated in a subsequent similarly designed 4-week 
RCT: pregabalin was significantly superior over placebo 
(mean difference=3.9, p=0.001) as measured by HARS.
17 
The superiority of pregabalin along with rapid improve-
ment over placebo was consistently demonstrated in other 
RCTs, indicating that pregabalin may be clearly useful 
and has definite clinical evidence for GAD.
1,19 Interest-
ingly, pregabalin 400 or 600 mg/d was compared with 
venlafaxine 75 mg/d, or placebo for 6-week (n=421). Pre-
gabalin at both dosages was found be equivalent to the 
effect of venlafaxine in improvement of HARS with sig-
nificant differences comparing with placebo.
20 Aforemen-
tioned findings ultimately suggest that pregabalin has 
similar and comparable efficacy with contemporary anti-
depressant and benzodiazepines as well as having partly 
favorable adverse events profile compared to benzodia-
zepines in the treatment of GAD. Although it was not ro-
bust as much as seen in GAD trials, pregabalin 600 mg/d 
was also effective in the treatment of SAD.
16 In line with 
such RCTs, the effect size (ES) of pregabalin (ES=0.5) 
for GAD treatment was found be higher than contem-
porary antidepressants, serotonin-norepinephrine reuptake 
inhibitors (SNRIs)(ES=0.42) and selective serotonin re-
uptake inhibitors (SSRIs)(ES=0.36), and bezodiazepines  
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(ES=0.38).
21 
According a post-hoc analysis of the existing clinical 
trial database, pregabalin at doses of 150 mg/d (32.1%), 
300-450 mg/d (40.1%) and 600 mg/d (36.7%) was asso-
ciated with statistically significant improvement in end-
point Hamilton Depression Rating Scale-17 item (HAMD-
17) scores compared to placebo (22.8%).
18 Moreover, 
pregabalin retained superior efficacy even in patients with 
more prominent depressive symptoms compared to pla-
cebo, especially demonstrating the most beneficial re-
sponse with pregabalin 300-450 mg/d. This finding may 
indicate the potential of pregabalin as augmentation the-
rapy for patients with treatment resistance, partially re-
sponding to current antidepressants or with comorbid anx-
iety disorders when subsequent RCTs replicate similar 
results.  
Pregabalin was also effective in the treatment of benzo-
diazepine withdrawal symptoms in even chronic abusers.
22-24 
This issue is in particular important since many psychi-
atric patients as well as those seen in general practice have 
been easily exposed to abuse or dependence, which may 
lead to comorbid psychiatric and medical conditions as 
well as increment of individual and public health care 
costs. Hence pregabalin may be quite helpful when it could 
be applicable to the biological detoxification programs. 
In the author’s clinical experience, pregabalin was very 
useful as augmentation therapy in the treatment of post-
traumatic stress disorder (PTSD) patients who were par-
tially responsive to current antidepressants as well.
25 The 
action mode of pregabalin, that is, a reduction of excita-
tory neurotransmitters such as glutamate fits well with 
major symptoms of PTSD, i.e., hypervigilance and hy-
perarousal.
26  
 
Future Direction and Conclusion 
 
We may expect a substantial role of pregabalin for pa-
tients with depression, anxiety disorders, substance abuse 
and dependence, aggression and violence, interictal psy-
chosis, sleep disturbance, unexplained somatic complaints 
(predominantly widespread pain), PTSD, neurodegenera-
tive diseases and bipolar affective disorders (Figure 1). 
Future researches should include whether or not pre-
gabalin has early improvement effect in depression or 
anxiety disorders or any treatment effects as augmenta-
tion therapy for such patients who did not respond to 
conventional treatment options. Predictor analysis on re-
sponse to pregabalin will be intriguing well. Given meth-
odological pitfalls in currently available data, additional 
works are also needed to determine whether these favor-
able findings for pregabalin hold true over the long-term 
period, and whether patients having several comorbid 
psychiatric disorders are also responsive to pregabalin. 
Direct comparison studies will be also necessary to con-
firm differential outcomes between pregabalin and contem-
porary treatment regimes.   
 
Acknowledgments 
This work was supported by a grant from the Medical Research Center, 
Korea Science and Engineering Foundation, Republic of Korea (R13-
2002-005-04001-0). 
 
REFERENCES 
1. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, 
Bielski RJ, et al. Pregabalin for treatment of generalized anxiety dis-
order: a 4-week, multicenter, double-blind, placebo-controlled trial of 
pregabalin and alprazolam. Arch Gen Psychiatry 2005;62:1022-1030. 
2. Gajraj NM. Pregabalin: its pharmacology and use in pain management. 
Anesth Analg 2007;105:1805-1815. 
3. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, 
Corbin AE, et al. Pregabalin for the treatment of fibromyalgia syn-
drome: results of a randomized, double-blind, placebo-controlled trial. 
Arthritis Rheum 2005;52:1264-1273. 
4. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, 
et al. A randomized, double-blind, placebo-controlled, phase III trial of 
pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 
2008;35:502-514. 
5. Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig 
GM, et al. Fibromyalgia relapse evaluation and efficacy for durability 
of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-
controlled trial with pregabalin. Pain 2008;136:419-431. 
6. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, 
et al. A 14-week, randomized, double-blinded, placebo-controlled mo-
notherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008; 
9:792-805. 
7. Zohar J, Matar MA, Ifergane G, Kaplan Z, Cohen H. Brief post-stres-
sor treatment with pregabalin in an animal model for PTSD: short-
term anxiolytic effects without long-term anxiogenic effect. Eur Neu-
ropsychopharmacol 2008;18:653-666. 
8. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy 
volunteers to assess the effects on sleep of pregabalin compared with 
FIGURE 1. Pharmacological characteristics and potential useful-
ness of pregabalin in psychiatric disorders. 
Substance abuse 
and dependence 
Sleep 
 disturbance 
Anxiety 
Painful somatic 
symptoms 
Post-traumatic 
stress disorder 
Depression 
Cognitive  
dysfunction 
Pregabalin 
 
 Structural derivative  ▶ of gamma-aminobutyric acid (GABA) 
 Binding to ▶  the α2-δ subunit protein of voltage-gated calcium 
channels 
▶ Reduction of the release of neurotransmitters, i.e., glutamate, 
noradrenaline, serotonin, dopamine, and substance P 
» Effective as analgesic, anticonvulsant, anxiolytic and neuro-
tropic agents  
 
 
 
 
Pregabalin for Psychiatry 
58 Psychiatry Invest 2009;6:55-58 
alprazolam and placebo. Sleep 2005;28:187-193. 
9. Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and positive-
internal-controlled (alprazolam) investigation of the cognitive and psy-
chomotor profile of pregabalin in healthy volunteers. Psychopharmaco-
logy (Berl) 2005;183:133-143. 
10. Ha KY, Kim YH, Rhyu KW, Kwon SE. Pregabalin as a neuropro-
tector after spinal cord injury in rats. Eur Spine J 2008;17:864-872. 
11. André V, Rigoultot MA, Koning E, Ferrandon A, Nehlig A. Long-term 
pregabalin treatment protects basal cortices and delays the occurrence 
of spontaneous seizures in the lithium-pilocarpine model in the rat. 
Epilepsia 2003;44:893-903. 
12. Ratcliffe GE, Enns MW, Belik SL, Sareen J. Chronic pain conditions 
and suicidal ideation and suicide attempts: an epidemiologic perspec-
tive. Clin J Pain 2008;24:204-210. 
13. Pae CU, Luyten P, Marks DM, Han C, Park SH, Patkar AA, et al. The 
relationship between fibromyalgia and major depressive disorder: a 
comprehensive review. Curr Med Res Opin 2008;24:2359-2371. 
14. Lundberg G, Gerdle B. Tender point scores and their relations to signs 
of mobility, symptoms, and disability in female home care personnel 
and the prevalence of fibromyalgia syndrome. J Rheumatol 2002;29: 
603-613. 
15. Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler 
R, et al. Pregabalin in generalized anxiety disorder: a placebo-controll-
ed trial. Am J Psychiatry 2003;160:533-540. 
16. Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein 
MB, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety 
disorder: a placebo-controlled, multicenter study. J Clin Psychophar-
macol 2004;24:141-149. 
17. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, 
Targum SD, et al. A randomized, double-blind, placebo-controlled, 
fixed-dose, multicenter study of pregabalin in patients with generaliz-
ed anxiety disorder. J Clin Psychopharmacol 2003;23:240-249. 
18. Stein DJ, Baldwin DS, Baldinetti F, Mandel F. Efficacy of pregabalin 
in depressive symptoms associated with generalized anxiety disorder: 
a pooled analysis of 6 studies. Eur Neuropsychopharmacol 2008;18: 
422-430. 
19. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in 
the treatment of generalized anxiety disorder: double-blind, placebo-
controlled comparison of BID versus TID dosing. J Clin Psychophar-
macol 2005;25:151-158. 
20. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Ef-
ficacy and safety of pregabalin in the treatment of generalized anxiety 
disorder: a 6-week, multicenter, randomized, double-blind, placebo-
controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 
2006;67:771-782. 
21. Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of phar-
macologic treatments for generalized anxiety disorder. J Psychophar-
macol 2007;21:864-872. 
22. Biermann T, Bleich S, Kornhuber J, Hillemacher T. Pregabalin in 
benzodiazepine withdrawal. Pharmacopsychiatry 2007;40:292-293. 
23. Oulis P, Konstantakopoulos G, Kouzoupis AV, Masdrakis VG, Kara-
katsanis NA, Karapoulios E, et al. Pregabalin in the discontinuation of 
long-term benzodiazepines’ use. Hum Psychopharmacol 2008;23:337-
340. 
24. Stevens JC, Pollack MH. Benzodiazepines in clinical practice: consi-
deration of their long-term use and alternative agents. J Clin Psychi-
atry 2005;66 Suppl 2:21-27. 
25. Pae CU, Marks DM, Han C, Masand PS, Patkar AA. Pregabalin 
augmentation of antidepressants in patients with accident-related post-
traumatic stress disorder: an open label pilot study. Int Clin Psycho-
pharmacol 2009;24:29-33. 
26. Cortese BM, Phan KL. The role of glutamate in anxiety and related 
disorders. CNS Spectr 2005;10:820-830. 
 
 
 
 
 
 
 
 
 
 